Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov:39 Hors série n° 1:47-53.
doi: 10.1051/medsci/2023143. Epub 2023 Nov 17.

[GDF5: a therapeutic candidate for combating sarcopenia]

[Article in French]
France Piétri-Rouxel  1 , Sestina Falcone  1 , Massiré Traoré  1
Affiliations
Free article

[GDF5: a therapeutic candidate for combating sarcopenia]

[Article in French]
France Piétri-Rouxel et al. Med Sci (Paris). 2023 Nov.
Free article

Abstract
in English, French

Sarcopenia is a complex age-related muscular disease affecting 10 to 16 % of people over 65 years old. It is characterized by excessive loss of muscle mass and strength. Despite a plethora of studies aimed at understanding the physiological mechanisms underlying this pathology, the pathophysiology of sarcopenia remains poorly understood. To date, there is no pharmacological treatment for this disease. In this context, our team develop therapeutic approaches based on the GDF5 protein to counteract the loss of muscle mass and function in various pathological conditions, including sarcopenia. After deciphering one of the molecular mechanisms governing GDF5 expression, we have demonstrated the therapeutic potential of this protein in the preservation of muscle mass and strength in aged mice.

Title: GDF5 - Un candidat thérapeutique dans la lutte contre la sarcopénie.

Abstract: La sarcopénie est une maladie musculaire complexe liée à l’âge qui affecte entre 10 à 16 % des personnes âgées de plus 65 ans. Elle se caractérise par une perte excessive de la masse musculaire et de la force. Malgré la multitude d’études visant à comprendre les mécanismes physiologiques qui sous-tendent cette pathologie, la physiopathologie de la sarcopénie reste encore mal comprise. A ce jour, il n’existe pas de traitement pharmacologique pour lutter contre cette pathologie. Dans ce contexte, notre équipe développe des approches thérapeutiques basées sur l’utilisation de la protéine GDF5 pour contrecarrer la perte de la masse et de la fonction musculaire dans diverses conditions pathologiques dont la sarcopénie. Après avoir décrypté un des mécanismes moléculaires régulant l’expression du GDF5, nous avons démontré le potentiel thérapeutique de cette protéine dans la préservation de la masse et la force musculaire chez les souris âgées.

PubMed Disclaimer

References

    1. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care 2004 ; 7 : 405–410.
    1. Mitchell WK, Williams J, Atherton P, et al. Sarcopenia, Dynapenia, and the Impact of Advancing Age on Human Skeletal Muscle Size and Strength; a quantitative Review. Front Physiol 2012 ; 3 : 260.
    1. Cao L, Morley JE. Sarcopenia Is Recognized as an Independent Condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code. J Am Med Dir Assoc 2016 ; 17 : 675–677.
    1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019 ; 48 : 16–31.
    1. Gonthier R. Epidemiology, morbidity, mortality, cost to society and the individual, and main causes for falls. Bull Acad Natl Med 2014 ; 198 : 1025–1039.

Publication types

Substances

LinkOut - more resources